Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer

Trifluridine/Tipiracil is an advanced oral cytotoxic agent indicated for metastatic colorectal cancer and certain types of advanced gastric cancer. It works through a dual mechanism: inhibiting thymidine synthase and incorporating directly into DNA to disrupt replication. While it offers significant survival benefits, managing its specific toxicity profile is essential for optimal patient care.

1. Hematological Toxicity: The Primary Concern

The most prominent dose-limiting toxicity is myelosuppression, particularly neutropenia. Blood counts typically reach their nadir around day 14 of the cycle. Thrombocytopenia and anemia are also common, necessitating regular monitoring. A complete blood count (CBC) must be performed before each cycle. Dose delays or reductions, along with growth factor support, are critical components of safety management.

2. Gastrointestinal Adverse Reactions

Nausea, vomiting, and diarrhea are frequently observed, usually starting in the first week. Prophylactic antiemetics (such as 5-HT3 antagonists) and prompt use of antidiarrheals (like loperamide) are recommended. Dietary adjustments, including small, frequent meals of low-fiber foods, help mitigate symptoms. Maintaining hydration and electrolyte balance is vital.

3. Non-Hematological Manifestations

Fatigue tends to be cumulative across cycles. Skin toxicities, such as palmar-plantar erythrodysesthesia (hand-foot syndrome), require protective measures like avoiding friction and using emollients. Mucosal inflammation, including stomatitis, should be managed with good oral hygiene and supportive care.

4. Monitoring and Dose Modification

Transient elevations in liver enzymes may occur. The cornerstone of management is proactive dose adjustment. If toxicities arise, the dose is typically reduced to 75% of the standard level. For geriatric or frail patients, extending the treatment-free interval may improve tolerability.

5. Conclusion

Trifluridine/Tipiracil represents a valuable oral option in the oncologist’s arsenal. By balancing rigorous safety monitoring with effective symptom control, clinicians can maximize therapeutic outcomes while preserving the patient's quality of life.